New drug cocktail aims to fight tough childhood cancer
NCT ID NCT07318831
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial tests a combination of four drugs—chidamide, dinutuximab beta, irinotecan, and temozolomide—in 27 children whose neuroblastoma has returned or not responded to standard treatment. The goal is to see how well the regimen controls the cancer and to monitor side effects closely. The study is currently recruiting participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Chidamide, Dinutuximab Beta, Irinotecan, and Temozolomide
- What this could lead to
- If this works, it could offer a new treatment option for children with hard-to-treat neuroblastoma, potentially improving cancer control and survival.
- What could go wrong
- This is a small, early-phase trial with only 27 participants, so results may not apply to all children. The drug combination may cause significant side effects, and it is not a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROBLASTOMA (NB) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Tianjin Medical University Cancer Institute & Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.